Shionogi Of Japan Expects Peramivir Approval In January For Flu
This article was originally published in PharmAsia News
Japan's Shionogi expects to begin selling peramivir, an intravenous flu drug, in Japan as early as January, when the company hopes to receive health ministry approval
You may also be interested in...
Merck & Co.'s vericiguat, an sGC stimulator, was approved for heart failure but it enters a competitive space with a narrow indication.
A top executive at the Swedish company spoke with Medtech Insight about how the mobility and data reliability of 5G cellular technology will change how medtech manufacturers design their products.
Roche's Actemra is a major player in this space, but Humanigen is looking to take it on directly.